



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Aleksandar Knezevic**

Organisation/Company: Sibenik General Hospital

Country: Croatia

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
02/2011-09/2011	Bayer d.o.o., Zagreb, Croatia	Xarelto (rivaroxaban)	prevention and treatment of venous thromboembolism
12/2012-12/2012	Merck d.o.o., Zagreb, Croatia	Concor AM (bisoprolol/amlodipine)	treatment of hypertension

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

Classified as public by the European Medicines Agency

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
12/2008-03/2012	Eli Lilly	prasugrel	prevention of atherothrombotic events in patients with acute coronary syndrome
03/2009-10/2010	Sanofi	semuloparin	prevention of thromboembolism in cancer patients
06/2009-04/2010	Bayer	Xarelto (rivaroxaban)	prevention of DVT in medical patients
09/2009-04/2013	Daiichi Sankyo Inc.	edoxaban	prevention of embolic events in patients with atrial fibrillation
05/2011-03/2013	Takeda	alogliptin	cardiovascular outcomes in patients with diabetes and acute coronary syndrome
07/2013-01/2014	Takeda	Tak 875	treatment of diabetes
08/2013-08/2019	Boehringer Ingelheim Pharmaceuticals	Pradaxa (dabigartan)	prevention of embolism in patients with atrial fibrillation
01/2014-01/2016	Intarcia	new therapeutic system for delivery of exenatide	treatment of diabetes
03/2014-01/2015	Boehringer Ingelheim Pharmaceuticals	linagliptin	cardiovascular and renal outcomes in patients with diabetes
04/2014-03/2016	Portola	betrixaban	prevention of DVT in medical patients
07/2014-12/2014	Laboratoires SMB	PRAVAFENIX (pravastatin/fenofibrate)	treatment of dislipidaemia in high risk person for CVD
12/2014-05/2019	Novartis	LCZ696	treatment of CHF in patients with preserved ejection fraction
03/2016-04/2018	Bayer	rivaroxaban	prevention of DVT in medical patients
05/2017-09/2018	BMS	apixaban	prevention of embolism in patients with atrial fibrillation after PCI
06/2017-10/2017	Daiichi Sankyo Inc.	edoxaban	prevention of embolism in patients with atrial fibrillation and high GFR
07/2017-(current)	Esperion Therapeutics	bependoic acid	treatment of dislipidaemia in high risk person for CVD intolerant to statins

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

3

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

Head of Working Group for Cardiovascular Pharmacology and Drug Therapy of Croatian Society of Cardiology  
 Member of Working Group for Cardiovascular Pharmacology and Drug Therapy of European Society of Cardiology  
 Member of Drug Safety Committee of Croatian Medicines Agency

## 2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Aleksandar Knezevic
Date:	2021-11-09

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*